MarketPulse

Nektar Therapeutics

5 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Pomerantz Llp

Eos Energy Shares Crater 39% Amid Production Woes, Triggering Class Action Lawsuit

Eos Energy stock plummeted 39.44% after missing earnings targets due to production and quality control issues, prompting Pomerantz Law Firm to file securities fraud class action lawsuit.
EOSEAQSTNKTRsecurities fraudclass action lawsuit
The Motley FoolThe Motley Fool··Eric Volkman

Nektar Therapeutics Surges 18% on Positive Alopecia Drug Trial Results

Nektar Therapeutics surges 18% after reporting positive phase 2b results for rezpegaldesleukin, an investigational alopecia areata treatment, advancing into later-stage trials.
NKTRclinical trial resultsbiotech stock
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Nektar Therapeutics Faces Securities Lawsuit Over REZOLVE-AA Trial Misstatements

Rosen Law Firm initiates securities class action against $NKTR for alleged false statements regarding enrollment protocols in REZOLVE-AA trial. Lead plaintiff deadline: May 5, 2026.
NKTRsecurities class actionlead plaintiff
GlobeNewswire Inc.GlobeNewswire Inc.··The Schall Law Firm

Nektar Therapeutics Faces Class Action Over REZOLVE-AA Trial Misstatements

Nektar Therapeutics faces class action lawsuit alleging securities fraud over alleged REZOLVE-AA trial misstatements involving improper patient enrollment procedures.
NKTRsecurities fraudclass action lawsuit
BenzingaBenzinga··Business Wire

Nektar Therapeutics Faces Securities Fraud Lawsuit Over Misleading Trial Claims

Schall Law Firm seeks investors in class action against $NKTR over alleged false statements regarding REZOLVE-AA trial enrollment and integrity.
NKTRsecurities fraudclass action lawsuit